In fact, triple-negative and HER2-overexpressing breast carcinomas present the higher tissue glucose metabolism, measured by 18 F-FDG PET scan, in comparison with the other breast cancer molecular subtypes [17], reinforcing the association between glycolytic metabolism and breast cancer poor prognosis. This evidence concerns the gene ERBB2 and breast cancer.